Cotización Alector - ALEC

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

3.635

Postura de Compra

1.46

Postura de Venta

3.79

Volume Operado de la Acción

0.00 Rango del Día 0.00

3.57 Rango de 52 semanas 8.90

Capitalización de Mercado [m]

355.985M

Precio Anterior

3.635

Precio de Apertura

Hora

3.71

Última hora de negociación

03:08:00

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

596,452

Acciones en circulación

97,932,605

Rendimiento del Dividendo

Ratio Precio/Utilidad

-2.73

Beneficio por acción (BPA)

-1.33

turnover

97.06M

Beneficio neto

-130.39M

Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to... Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101. Mostrar más

Sector

Biological Pds,ex Diagnstics

Industria

Biological Pds,ex Diagnstics

Sitio web

www.alector.com

Sede

Wilmington, Delaware, USA

Fundado

Alector Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALEC. The last closing price for Alector was US$3.64. Over the last year, Alector shares have traded in a share price range of US$ 3.57 to US$ 8.90.

Alector currently has 97,932,605 shares in issue. The market capitalisation of Alector is US$355.99 million. Alector has a price to earnings ratio (PE ratio) of -2.73.

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-1.525	-29.5542635659	5.16	5.16	3.57	774916	3.95938892	CS
4	-1.065	-22.6595744681	4.7	6.14	3.57	736564	4.92511361	CS
12	-1.665	-31.4150943396	5.3	6.37	3.57	596452	5.04971081	CS
26	-1.745	-32.4349442379	5.38	6.78	3.57	603846	5.10919485	CS
52	-1.165	-24.2708333333	4.8	8.9	3.57	623745	5.73388177	CS
156	-17.7284	-82.984918131	21.3634	24.005	3.57	618156	8.64900111	CS
260	-12.355	-77.2670419012	15.99	45	3.57	677039	15.03918715	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
WORXSCWorx Corporation	US$ 1.98 (102.04%)	16.34M
AKTSAkoustis Technologies Inc	US$ 0.1321 (51.66%)	57.77M
PETWag Group Company	US$ 0.303 (44.22%)	18.31M
ESGROEnstar Group Ltd	US$ 28.00 (40.92%)	28
CCECCapital Clean Energy Carriers Corporation	US$ 24.99 (34.72%)	11
WSBFWaterstone Financial Inc	US$ 9.00 (-40.98%)	4
TRSTriMas Corporation	US$ 15.62 (-40.79%)	3
BCAXBicara Therapeutics Inc	US$ 11.00 (-40.15%)	212
PYXSPyxis Oncology Inc	US$ 2.43 (-36.39%)	209.56k
XNCRXencor Inc	US$ 15.11 (-36.30%)	2
AKTSAkoustis Technologies Inc	US$ 0.1321 (51.66%)	57.77M
PETWag Group Company	US$ 0.303 (44.22%)	18.31M
WORXSCWorx Corporation	US$ 1.98 (102.04%)	16.34M
XTKGX3 Holdings Company Ltd	US$ 0.0775 (-13.89%)	10.83M
CRKNCrown Electrokinetics Corporation	US$ 0.9853 (25.41%)	5.59M